# OH2 Injection in Combination With HX008 for Melanoma.

Source: https://onco.cc/trials/nct04616443/  
OnCo record `nct04616443` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pucotenlimab in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.

## Summary

OH2 Injection in Combination With HX008 for Melanoma. is a phase 1/2 interventional study registered as NCT04616443 by Binhui Biopharmaceutical Co., Ltd., with 60 participants planned, started 2020-12-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: OH2 injection, HX008 injection. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04616443
- Phase: 1/2
- Setting: Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma
- Sponsor: Binhui Biopharmaceutical Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04616443: https://clinicaltrials.gov/study/NCT04616443

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- companies: [Binhui Biopharmaceutical](https://onco.cc/companies/binhui-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct04616443.json